11/21
07:30 am
vrca
Verrica Announces Pricing of $42.0 Million Public Offering
High
Report
Verrica Announces Pricing of $42.0 Million Public Offering
11/20
04:15 pm
vrca
Verrica Announces Proposed Public Offering [Yahoo! Finance]
High
Report
Verrica Announces Proposed Public Offering [Yahoo! Finance]
11/20
04:05 pm
vrca
Verrica Announces Proposed Public Offering
High
Report
Verrica Announces Proposed Public Offering
11/6
07:32 am
vrca
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Medium
Report
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
11/5
02:32 pm
vrca
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/5
07:00 am
vrca
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating.
High
Report
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating.
11/4
04:05 pm
vrca
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
High
Report
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
10/30
10:00 am
vrca
Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
Low
Report
Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
10/24
07:00 am
vrca
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
Medium
Report
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
10/21
01:13 pm
vrca
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target lowered by analysts at TD Cowen from $15.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target lowered by analysts at TD Cowen from $15.00 to $10.00. They now have a "buy" rating on the stock.
10/11
05:21 pm
vrca
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
Medium
Report
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
10/7
05:21 pm
vrca
Optinose Appoints Terry Kohler as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Optinose Appoints Terry Kohler as Chief Financial Officer [Yahoo! Finance]
10/7
05:10 pm
vrca
Optinose names Terry Kohler as CFO [Seeking Alpha]
Medium
Report
Optinose names Terry Kohler as CFO [Seeking Alpha]
10/4
11:58 am
vrca
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target lowered by analysts at Royal Bank of Canada from $13.00 to $11.00. They now have an "outperform" rating on the stock.
High
Report
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its price target lowered by analysts at Royal Bank of Canada from $13.00 to $11.00. They now have an "outperform" rating on the stock.
10/3
08:18 am
vrca
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
High
Report
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
10/2
01:12 pm
vrca
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "hold" rating re-affirmed by analysts at Brookline Capital Management.
High
Report
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "hold" rating re-affirmed by analysts at Brookline Capital Management.
10/2
07:30 am
vrca
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
High
Report
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
9/27
10:29 pm
vrca
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
High
Report
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
9/13
04:57 pm
vrca
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
Medium
Report
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
9/4
07:30 am
vrca
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
Medium
Report
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
8/26
09:04 am
vrca
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit? [Yahoo! Finance]
Medium
Report
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit? [Yahoo! Finance]